Dr. Frantz Le Devedec reports

AVICANNA AND LANGARA COLLEGE ANNOUNCE CANNABINOID-BASED TRANSLATIONAL RESEARCH COLLABORATION AND NSERC GRANT

Avicanna Inc. has entered a research collaboration with the Applied Research Centre at Langara College that will focus on Avicanna's proprietary formulations and pharmaceutical pipeline. This research collaboration has been awarded a peer-reviewed grant from the Natural Sciences and Engineering Research Council of Canada Applied Research and Development Grant for a period of two years starting Q2 2023.

Dr. Jessica Kalra's group at the Applied Research Centre at Langara College will be collaborating with Avicanna's research and development team to perform in vitro and in vivo research of the company's drug delivery systems and commercial formulations, including under the Rho Phyto brand. The outcomes of the research collaboration would look to gaining a better understanding of the absorption, pharmacokinetic and pharmacodynamic properties of the formulations, which may contribute toward product pipeline developments.

"We are thrilled to be collaborating with Dr. Kalra's group and look forward to create a deeper understanding of our proprietary cannabinoid formulations which may yield advancements in our drug candidates," said Dr. Frantz Le Devedec, executive vice-president of R&D at Avicanna.

"It is a very exciting time to be researching non-psychoactive pharmaceutically relevant cannabinoids, their impact on the body and how they can be best formulated to provide optimal therapeutic activity. Our team is delighted to have this opportunity to work with Avicanna to support the translation of cannabinoids from bench to bedside," stated Dr. Kalra.

Dr. Kalra is a research scientist in the Applied Research Centre at Langara College, an assistant professor of teaching in the faculty of pharmaceutical at the University of British Columbia and a staff scientist in the department of experimental therapeutics at the British Columbia Cancer Research Centre. Dr. Kalra has over 20 years of experience in drug discovery, cell and molecular research, including evaluating drug efficacy in various in vitro and in vivo models and developing novel nanoparticle formulations to address challenges to drug delivery that stems from heterogeneity of disease and/or solubility and lipophilicity of drug entities. The research team has expertise in formulation science and cell and tissue culture that supports the analysis of novel drug entities from a chemical and in vitro biology perspective.

About Avicanna Inc.

Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development that has led to the commercialization of more than 30 products across various market segments.

We seek Safe Harbor.